Crystalline form of a 3-phenoxymethylpyrrolidine compound
The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 0.01 to 95 wt % of a crystalline salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine and hydrochloric acid in a 1:1 molar ratio, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 8.78±0.20, 15.26±0.20, 19.08±0.20, 20.36±0.20, 21.50±0.20, and 25.46±0.20.
2. The pharmaceutical composition of claim 1 , where the crystalline salt is characterized by having one or more additional diffraction peaks at 2θ values selected from 26.42±0.20, 30.65±0.20, 28.91±0.20, 24.77±0.20, 14.42±0.20, 16.74±0.20, and 5.20±0.20.
3. The pharmaceutical composition of claim 1 , where the crystalline salt is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1 .
4. The pharmaceutical composition of claim 1 , where the crystalline salt is characterized by a differential scanning calorimetry trace which has a melting point of about 128° C.
5. The pharmaceutical composition of claim 1 , where the crystalline salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 2 .
6. The pharmaceutical composition of claim 1 , further comprising a secondary therapeutic agent selected from anti-Alzheimer's agents, anticonvulsants, antidepressants, anti-Parkinson's agents, dual serotonin-norepinephrine reuptake inhibitors, non-steroidal anti-inflammatory agents, norepinephrine reuptake inhibitors, opioid agonists, opioid antagonists, selective serotonin reuptake inhibitors, sodium channel blockers, sympatholytics, and combinations thereof.
7. The pharmaceutical composition of claim 1 , which comprises about 0.01 to 30 wt % of the crystalline salt.
8. The pharmaceutical composition of claim 7 , which comprises about 0.01 to 10 wt % of the crystalline salt.